InsiderSignal.AI

InsiderSignal.ai

XENE - Xenon Pharmaceuticals Inc.

Insider Sale by Mortimer Ian (Pres, CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

2 days ago, Mortimer Ian, serving as Pres, CEO at Xenon Pharmaceuticals Inc. (XENE), sold 7,308 shares at $55.23 per share, for a total transaction value of $403,584.00. Following this transaction, Mortimer Ian now holds 34,223 shares of XENE.

This sale represents a 18.00% decrease in Mortimer Ian's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, March 13, 2026 and publicly disclosed via SEC Form 4 filing on Friday, March 13, 2026, meaning the disclosure happened on the same day as the trade.

Xenon Pharmaceuticals Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Mortimer Ian

Mortimer Ian

Pres, CEO

Ian Mortimer is the President and Chief Executive Officer of Xenon Pharmaceuticals Inc. (NASDAQ: XENE), a clinical-stage biopharmaceutical company focused on developing therapies for neurological disorders, particularly epilepsy and rare CNS conditions. He has held this role since June 2021, after serving as President and Chief Financial Officer from March 2018, Corporate Secretary from June 2015 to March 2021, Chief Financial Officer and Chief Operating Officer from March 2015 to 2018, and Chief Financial Officer from October 2013 to 2015.[[1]](https://www.zoominfo.com/p/Ian-Mortimer/4053801)[[2]](https://www.bloomburton.com/finalist-member/ian-mortimer/) Mortimer brings over 25 years of biotechnology experience, starting in laboratory research before transitioning to finance. Prior to Xenon, he was Executive Vice President and Chief Financial Officer at Tekmira Pharmaceuticals Corporation (now Arbutus Biopharma) from 2007 to 2013, where he led its Nasdaq listing in 2010, and held various finance roles at Inex Pharmaceuticals from 1997 to 2007, becoming CFO in 2004. He holds a Bachelor of Science in Microbiology from the University of British Columbia and a Master of Business Administration from Queen's University. Mortimer serves on the BIOTECanada Board of Directors since 2023 and was a 2023 Bloom Burton Award finalist. Recently, on December 5 and 8, 2025, he sold 25,205 shares under a Rule 10b5-1 plan for $1.14 million, retaining 8,010 shares directly.[[3]](https://lifesciencesbc.ca/members/biotecanada-welcomes-xenon-ceo-ian-mortimer-to-board-of-directors/)[[4]](https://www.investing.com/news/insider-trading-news/ian-mortimer-xenon-pharma-ceo-sells-114m-in-shares-93CH-4399831)[[5]](https://www.youtube.com/watch?v=5ByoXqO3dOU)[[1]](https://www.zoominfo.com/p/Ian-Mortimer/4053801)

View full insider profile →

Trade Price

$55.23

Quantity

7,308

Total Value

$403,584.00

Shares Owned

34,223

Trade Date

Friday, March 13, 2026

2 days ago

SEC Filing Date

Friday, March 13, 2026

HEALTHCAREBIOTECHNOLOGY

About Xenon Pharmaceuticals Inc.

Company Overview

No company information available
View news mentioning XENE

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4757253

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime